Published 15 days ago • loading... • Updated 15 days ago

Poolbeg Pharma granted patent in Korea for POLB 001

Summary by DirectorsTalk Interviews

Poolbeg Pharma plc (LON:POLB), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, has announced that the Korean Intellectual Property Office has notified the Company of its official decision to grant Poolbeg’s Republic of Korea Immunomodulator II patent application providing protection to POLB 001 for the treatment of severe influenza to December 2038. POLB 001 is a po…

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

3 Articles

All

Left

Center

Right

Optimum Strategic Communications

Poolbeg Pharma plc – POLB 001 Patent Granted in Korea – Optimum Strategic Communications

Grant further strengthens Poolbeg’s global intellectual property (“IP”) portfolio 20 March 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces that the Korean Intellectual Property Office has notified the Company of its official decision to grant Poolbeg’s Republic of Korea Immunomodulator II patent …

15 days ago

Read Full Article